About Neogenix Oncology
Neogenix Oncology is a Healthcare company based in Great Neck (United States) founded in 2003, and was acquired by Precision Biologics in July 2012. Therapeutic and diagnostic antibodies are developed for cancer treatments. Neogenix Oncology has raised $15.85 million across 2 funding rounds from investors including Precision Biologics. The company was acqui-hired. Its focus areas include Life Sciences, Immunotherapy, Antibody and Immunomodulatory.
Company details
Neogenix Oncology was a clinical stage company, developing antibodies for the treatment of pancreatic, colon, lung, prostate,etc.. The lead candidate, NEO-101 (Ensituximab) is a monoclonal antibody (mAb) was in Phase IIa trials for colorectal and pancreatic cancer. Other candidates, NEO-201 and NEO-301, which were in preclinical stage for cancer indication. The was acquired by Precision Biologics in Sep 2012.
- Headquarters Great Neck, United States
- Stage Acquired
- SectorsHealthcare
- Website precision-biologics.com
- Social LinkedIn
- Acquired by Precision Biologics (Jul 2012)
- Total Equity Funding$15.85M (USD)
in 2 rounds
- Latest Funding Round$846.23K (USD), Series B
Oct 2010
- Investors
- Acquired byPrecision Biologics
(Jul 2012)
Funding Insights of Neogenix Oncology
Neogenix Oncology has successfully raised a total of $15.85M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $846.23 thousand completed in October 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $15.85M
- Total Rounds 2
- Last Round Series B — $846,225
- First Round $15M
(May 2009)
All 2 funding rounds of Neogenix Oncology with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2010 | $846,225 | Series B | – | – | – |
| May 2009 | $15M | Series B | – | – | – |
1 investors in total: 1 institutional.
Investors in Neogenix Oncology
Neogenix Oncology has secured backing from 1 investor. Prominent investors backing the company include Precision Biologics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Precision Biologics is focused on developing innovative cancer therapies. | 2012 | precision-biologics.com | Dallas, United States |
Investor details for Neogenix Oncology
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Neogenix Oncology
4 dated milestones of Neogenix Oncology across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Neogenix Oncology is founded.
- Funding First funding round of $15.0M.
- Funding Latest funding round, Series B, of $846K.
- Exit Acquired by Precision Biologics.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Neogenix Oncology (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Neogenix Oncology
Neogenix Oncology was founded in 2003 and raised its 1st funding round 6 years after it was founded.
Neogenix Oncology is headquartered in Great Neck, United States. It is registered at Great Neck, New York, United States.
Neogenix Oncology is a funded company, having raised a total of $15.85M across 2 funding rounds to date. The company's 1st funding round was a Series B of $15M, raised on May 2009.
Neogenix Oncology was a clinical stage company, developing antibodies for the treatment of pancreatic, colon, lung, prostate,etc.. The lead candidate, NEO-101 (Ensituximab) is a monoclonal antibody (mAb) was in Phase IIa trials for colorectal and pancreatic cancer. Other candidates, NEO-201 and NEO-301, which were in preclinical stage for cancer indication. The was acquired by Precision Biologics in Sep 2012.
Neogenix Oncology has 1 investor. Key investors include Precision Biologics.
Yes. Neogenix Oncology was acquired by Precision Biologics in July 2012.